# EDGAR Filing Document

**Accession Number:** 0001019034
**File Stem:** 0001437749-26-013905
**Filing Date:** 2026-4
**Character Count:** 15185
**Document Hash:** 4f2e722e35c4333df7682fa0252faf36
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-013905.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001437749-26-013905

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260428

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260429

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO KEY INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0001019034
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 411761861
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13463
- **FILM NUMBER:** 26917278

**BUSINESS ADDRESS:**
- **STREET 1:** 101 CRAWFORDS CORNER RD
- **STREET 2:** SUITE 4116
- **CITY:** HOLMDEL
- **STATE:** NJ
- **ZIP:** 07733
- **BUSINESS PHONE:** 7323591100

**MAIL ADDRESS:**
- **STREET 1:** 101 CRAWFORDS CORNER RD
- **STREET 2:** SUITE 4116
- **CITY:** HOLMDEL
- **STATE:** NJ
- **ZIP:** 07733

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SAC TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19961115

?xml version='1.0' encoding='ASCII'? bkyi20260429_8k.htm

--12-31

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 28, 2026

**BIO-key International, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br> (State or other jurisdiction of incorporation) | **1-13463**<br> (Commission File Number) | **41-1741861**<br> (I.R.S. Employer Identification No.) |

---

**101 Crawfords Corner Road**

**Suite 4116**

**Holmdel, NJ 07733**

(Address of principal executive offices) (Zip Code)

**(732) 359-1100**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock | BKYI | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 3.03**  | **Material Modification to Rights of Security Holders.** |

---

To the extent required by Item 3.03 of Form 8-K, the information set forth under Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

---

| | |
|:---|:---|
| **Item 5.03** | **Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.** |

---

As previously reported, at a special meeting (the "<u>Special Meeting</u>") of stockholders of BIO-key Intentional, Inc. (the "<u>Company</u>") convened on April 20, 2026, the stockholders of the Company approved an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's common stock in the range of 1-for-2 to 1-for-10, with the final decision of whether to proceed with the reverse stock split and the exact ratio and timing of the reverse stock split to be determined by the Board, in its discretion, no later than May 6, 2026 (the "<u>Proposal</u>"). A more detailed summary of the Proposal can be found in the definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on March 16, 2026.

After the Special Meeting, the Board set the reverse stock split ratio at 1-for-10, and on April 28, 2026, the Company filed a Certificate of Amendment (the "<u>Certificate of Amendment</u>") with the Secretary of State of the State of Delaware to effect the reverse stock split. The Certificate of Amendment will become effective at 5:00 p.m., Eastern Time, on April 29, 2026. The Common Stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis on April 30, 2026 under a new CUSIP number, 09060C606.

At the effective time of the 1-for-10 reverse stock split, every 10 issued and outstanding shares of common stock will be converted into one (1) issued and outstanding share of common stock, and the total outstanding shares of Common Stock will be reduced from approximately 10,852,118 to approximately 1,085,212. The number of authorized shares and the par value per share will remain unchanged. No fractional shares will be issued in connection with the reverse stock split. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.

The foregoing description of the Certificate of Amendment is not complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On April 28, 2026, the Company issued a press release announcing the effectiveness of the reverse stock split, which is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

*(d) <u>Exhibits</u>.* 

---

| | |
|:---|:---|
| 3.1 | [Certificate of Amendment (filed herewith)](ex_952848.htm) |
| 99.1 | [Press Release dated April 28, 2026 (filed herewith)](ex_952849.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | BIO-KEY INTERNATIONAL, INC.  | BIO-KEY INTERNATIONAL, INC.  |
| Date: April 29, 2026  |  |  |
|  | By: | /s/ Cecilia C. Welch |
|  |  | Cecilia C. Welch <br> Chief Financial Officer |

---

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT**

**TO THE**

**CERTIFICATE OF INCORPORATION**

**OF**

**BIO-KEY INTERNATIONAL, INC.**

------

**Pursuant to Section 242 of the**

**General Corporation Law of the State of Delaware**

------

BIO-key International, Inc., a Delaware corporation (the "***Corporation***"), does hereby certify as follows:

FIRST: Upon the filing and effectiveness (the "***Effective Time***") pursuant to the General Corporation Law of the State of Delaware (the "***DGCL***") of this Certificate of Amendment to the Certificate of Incorporation of the Corporation, each ten (10) shares of the Corporation's common stock, par value $0.0001 per share (the "***Common Stock***"), issued and outstanding or held by the Corporation in treasury stock immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock without any further action by the Corporation or the holder thereof, subject to the treatment of fractional interests as described below. Notwithstanding the immediately preceding sentence, no fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares, will be entitled to rounding up of their fractional share to the nearest whole share. No stockholder will receive cash in lieu of fractional shares. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (the "***Old Certificates***") shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the adjustment for fractional shares as described above.

SECOND: The foregoing amendment was duly adopted in accordance with Section 242 of the DGCL.

THIRD: This Certificate of Amendment shall become effective at 5:00 pm eastern time on April 29, 2026.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its undersigned officer this 28<sup>th</sup> day of April 2026.

---

| | |
|:---|:---|
| BIO-KEY INTERNATIONAL, INC.  | BIO-KEY INTERNATIONAL, INC.  |
| By: | /s/ Michael W. DePasquale |
|  | Name: Michael W. DePasquale  |
|  | Title: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Following Stockholder Approval, BIO-key Announces 1-for-10 Reverse Stock Split**

**Holmdel, NJ** – **April 28, 2026** – <u>**BIO-key**® **International, Inc.**</u> (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, today announced that it has approved a 1-for-10 reverse stock split that will become effective with the commencement of trading on April 30, 2026.

BIO-key stockholders approved a proposal last week to allow the Board to proceed with a reverse split to assist the Company in its effort to regain compliance with the minimum bid price requirement.

BIO-key had approximately 10.9 million shares of common stock issued and outstanding as of April 28, 2026. After giving effect to the 1-for-10 reverse stock split, BIO-key will have approximately 1.1 million shares of common stock issued and outstanding.

BIO-key CEO Michael DePasquale commented, "The Board's decision to set the ratio at 1-for-10 was intended to position our common stock for minimum bid price compliance as we execute on our growth and profitability goals in 2026 and beyond."

**About BIO-key International, Inc. (**<u>**www.BIO-key.com**</u>**)**

BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud-hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

**BIO-key Safe Harbor Statement**

All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to migrate Swivel Secure customers to BIO-key and Portal Guard offerings; our ability to execute definitive agreements with Fiber Food Systems and/or its customers to utilize our access management solutions; our ability to integrate our solutions into any of Fiber Food System's offerings; fluctuations in foreign currency exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; the impact of tariffs and other trade barriers which may make it more costly for us to import inventory from China and Hong Kong and certain product components from South Korea; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence of non-compliance with Securities and Exchange Commission ("SEC") and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to continue to maintain effective internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.

**Engage with BIO-key:**

---

| | |
|:---|:---|
| Facebook – Corporate: | <u>https://www.facebook.com/BIOkeyInternational/</u> |
| LinkedIn – Corporate: | <u>https://www.linkedin.com/company/bio-key-international</u> |
| X – Corporate: | <u>@BIOkeyIntl</u> |
| X – Investors: | <u>@BIO_keyIR</u> |
| StockTwits: | <u>BIO_keyIR</u> |

---

**Investor Contacts:**

William Jones, David Collins

Catalyst IR

<u>**BKYI@catalyst-ir.com**</u> or 212-924-9800